advances in antibody-based hiv-1 vaccines development
Clicks: 174
ID: 158843
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
174 views
20 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #29 of 33 articles by views in Tuberkuloz ve toraks
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Despite the great success of antiretroviral therapy, both in the treatment and prevention of HIV-1 infection, a vaccine is still urgently needed to end the epidemic [...]
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (26 words).
Try re-searching for a better abstract.
| Reference Key |
dietrich2020vaccinesadvances
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Ursula Dietrich |
| Journal | Tuberkuloz ve toraks |
| Year | 2020 |
| DOI |
10.3390/vaccines8010044
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.